Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism [2]

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1384-1386

  Shetty, Ranjith ^a   Seddighzadeh, Ali ^a   Parasuraman, Sudha ^a,b   Vallurupalli, Neelima G ^c   Gerhard Herman, Marie ^a   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FONDAPARINUX; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADULT; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DEEP VEIN THROMBOSIS; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HAIR LOSS; HEMATOCRIT; HEMATOMA; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LETTER; LONG TERM CARE; LUNG EMBOLISM; MALE; MONOTHERAPY; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYSACCHARIDES; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 36948998584     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0394     Document Type: Letter

References (9)

1. Petitou M, Duchaussoy P, Herbert JM, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.
2. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustments methods in clinical trials. Statistics Med 1997; 16: 2529-2542.
3. Beckman JA, Dunn K, Sasahara AA, et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003; 89: 953-958.
4. Kucher N, Quiroz R, Mckean S, et al. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Med 2005; 10: 251-256.
5. Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
6. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
7. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
8. Wittkowsky AK, Downing J, Blackburn J et al. Warfarin-related outcome in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137-141.
9. Arixtra Dosing and Administration. GlaxoSmith-Kline. Available at: http://www.arixtra.com/dosing.htm. Accessed March 12, 2007.